Efaverinz and nano-gold-loaded mannosylated niosomes: a host cell-targeted topical HIV-1 prophylaxis via thermogel system
Source abstract
Abstract
Sexual dissemination of Human Immunodeficiency Virus-1 (HIV-1) is the prime mode of its spread. Topical microbicidal approach has gained much attention, but no real success is observed till date, either due to toxicity or resistance of active moieties and the lack of efficient drug delivery approaches. In this research protocol, a unique combination approach of a standard drug moiety, that is, Efaverinz (EFV) and a nanometal, that is, gold nanoparticles (GNPs) was tried. Both these candidates were delivered through a mannosylated niosomal system, to exploit protein (lectins present on HIV host cells) - carbohydrate (oligosaccharides such as mannan present on HIV gp-120 receptor) interaction. GNPs (10.4 nm average size) were entrapped inside the aqueous core, whereas lipophilic EFV was loaded in the bilayer membrane. Results demonstrated a significant increase in antiviral activity when EFV was fired with GNPs. Delivery of this combination via mannosylated niosomes proved to be a perfect approach with exceedingly well potential compared to non liganded niosomal system. A thermosensitive gel vehicle was prepared and the loaded niosomes were dispersed in it to have a nanogel system. The optimized formulation was evaluated for its prophylactic activity and the results showed completely inhibited viral dissemination at folds dilution levels.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: HIV Research and Treatment · Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Indo-Soviet Friendship College of Pharmacy, DBT Lab
Centre for Nanosciences, Department of Chemical Engineering, Indian Institute of Technology
Department of Virology, Haffkine Institute for Training Research and Testing
Head, Department of Microbiology, Grant Medical College, Sir JJ hospital
Department of Pharmaceutics, ISF College of Pharmacy
Funding
Department of Biotecthnology · Punjab State Council of Science and Technology
References (43)
Show source-provided references
1. Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. Aids Rev. 2012;14:62–77.
2. 10.1016/j.ejps.2014.09.01910.1016/j.ejps.2014.09.019 ↗
3. 10.2174/138161282166615091709421510.2174/1381612821666150917094215 ↗
4. 10.1097/INF.000000000000122410.1097/INF.0000000000001224 ↗
5. 10.1517/13543784.11.8.107710.1517/13543784.11.8.1077 ↗
6. 10.1016/j.addr.2016.01.01710.1016/j.addr.2016.01.017 ↗
7. 10.1097/QCO.0b013e328334de6d10.1097/QCO.0b013e328334de6d ↗
8. 10.1002/9781118663219.wbegss03510.1002/9781118663219.wbegss035 ↗
9. 10.1016/j.antiviral.2009.09.00810.1016/j.antiviral.2009.09.008 ↗
10. 10.1016/j.antiviral.2012.09.01510.1016/j.antiviral.2012.09.015 ↗
11. 10.1039/C5RA08274A10.1039/C5RA08274A ↗
12. 10.1007/s11051-010-9967-510.1007/s11051-010-9967-5 ↗
13. 10.1016/j.ijantimicag.2008.10.01010.1016/j.ijantimicag.2008.10.010 ↗
14. 10.1016/j.nano.2006.12.00110.1016/j.nano.2006.12.001 ↗
15. 10.1038/sj.clpt.610040010.1038/sj.clpt.6100400 ↗
16. 10.1186/1477-3155-8-1510.1186/1477-3155-8-15 ↗
17. 10.1039/C5RA16353F10.1039/C5RA16353F ↗
18. 10.1517/17425247.5.6.70310.1517/17425247.5.6.703 ↗
19. 10.1081/DDC-12002131810.1081/DDC-120021318 ↗
20. 10.1016/j.addr.2009.11.02110.1016/j.addr.2009.11.021 ↗
21. 10.2174/187221051099916041415081810.2174/1872210510999160414150818 ↗
22. 10.2147/IJN.S4588610.2147/IJN.S45886 ↗
23. 10.1038/physci241020a010.1038/physci241020a0 ↗
24. 10.1021/jp061667w10.1021/jp061667w ↗
25. 10.1016/j.ijpharm.2004.10.02610.1016/j.ijpharm.2004.10.026 ↗
26. 10.3109/10717544.2013.85527710.3109/10717544.2013.855277 ↗
27. Arora D, Khurana B, Kumar MS, et al. Oral immunization against hepatitis B virus using mannosylated bilosomes. Int J Recent Adv Pharma Res. 2011;1:45–51.
28. 10.1016/S0300-9084(01)01315-310.1016/S0300-9084(01)01315-3 ↗
29. 10.2174/15672011179525619210.2174/156720111795256192 ↗
30. 10.1007/s00216-007-1576-510.1007/s00216-007-1576-5 ↗
31. Ning M, Gu Z, Pan H, et al. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antifungal drug clotrimazole. Indian J Exp Biol. 2005;43:150–157.
32. 10.1021/nl080561510.1021/nl0805615 ↗
33. 10.1016/j.ejps.2009.02.02210.1016/j.ejps.2009.02.022 ↗
34. 10.2174/187412660080201006110.2174/1874126600802010061 ↗
35. 10.1016/j.ejpb.2008.04.02510.1016/j.ejpb.2008.04.025 ↗
36. 10.1016/j.ejpb.2006.12.01310.1016/j.ejpb.2006.12.013 ↗
37. Zhang T. 2013. Design and optimization of nanoformulation loaded with HIV microbicides University of Missouri-Kansas City.
38. 10.1016/S0010-7824(99)00010-410.1016/S0010-7824(99)00010-4 ↗
39. 10.1016/j.ijpharm.2006.03.01210.1016/j.ijpharm.2006.03.012 ↗
40. Stone A. 2009. Regulatory issuesin microbicide development.
41. 10.1211/jpp.57.9.001210.1211/jpp.57.9.0012 ↗
42. 10.1007/s13404-010-0001-610.1007/s13404-010-0001-6 ↗
43. 10.1016/S0378-5173(97)04904-110.1016/S0378-5173(97)04904-1 ↗